Emergent BioSolutions Awarded R&D Option valued At $41.9M For Continued Advanced Development And Procurement Of Ebanga Treatment For Ebola

Author: Benzinga Newsdesk | September 12, 2024 08:34am

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), valued at $41.9 million, for drug substance engineering and scale-up process validation, long term stability, and commercial readiness in support of its ongoing scale-up program for Ebanga™ (ansuvimab-zykl), a licensed treatment for Ebola virus disease (EVD).

Posted In: EBS